Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H28N2O3 |
| Molecular Weight | 332.4372 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(O)C(C)=C2CC[C@](C)(OC2=C1C)C(=O)N[C@@H]3CCCNC3
InChI
InChIKey=LZYWLEPSQNXESC-KUHUBIRLSA-N
InChI=1S/C19H28N2O3/c1-11-12(2)17-15(13(3)16(11)22)7-8-19(4,24-17)18(23)21-14-6-5-9-20-10-14/h14,20,22H,5-10H2,1-4H3,(H,21,23)/t14-,19+/m1/s1
| Molecular Formula | C19H28N2O3 |
| Molecular Weight | 332.4372 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
KH-176 is a drug candidate developed by pharmaceutical company Khondrion to treat a range of mitochondrial diseases including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders. KH176 has been granted Orphan Drug Designation for MELAS spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the USA. KH176 acts as a potent intracellular redox-modulating agent essential for the control of oxidative and redox pathologies.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:13:21 UTC 2023
by
admin
on
Sat Dec 16 09:13:21 UTC 2023
|
| Record UNII |
JCU3O35RDS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C170380
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY | |||
|
100000181147
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY | |||
|
72710875
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY | |||
|
1541170-75-5
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY | |||
|
JCU3O35RDS
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY | |||
|
10972
Created by
admin on Sat Dec 16 09:13:21 UTC 2023 , Edited by admin on Sat Dec 16 09:13:21 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> DERIVATIVE |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Mechanism of Action: Reactive oxygen species modulators; Orphan Drug Status: Yes for MELAS syndrome, Leigh disease, Mitochondrial disorders; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Phase I for Mitochondrial disorders, Preclinical for Parkinson's disease; Most Recent Events: 10 Aug 2015 KH 176 receives Orphan Drug status for MELAS syndrome in European Union, 01 May 2015 Phase-I clinical trials in Mitochondrial disorders (In volunteers) in Belgium (PO) (NCT02544217), 01 May 2015 Preclinical trials in Parkinson's disease in Netherlands (PO)
|
